

STATE OF MAINE

—
IN THE YEAR OF OUR LORD
TWO THOUSAND TWENTY-FIVE

—
S.P. 265 - L.D. 582

An Act to Require Health Insurance Carriers to Provide Coverage for Blood Testing for Perfluoroalkyl and Polyfluoroalkyl Substances

Be it enacted by the People of the State of Maine as follows:

Sec. 1. 24-A MRSA §4320-W is enacted to read:

§4320-W. Coverage for blood testing for PFAS

1. Definition. As used in this section, unless the context otherwise indicates, "perfluoroalkyl and polyfluoroalkyl substances" or "PFAS" means any member of the class of fluorinated organic chemicals containing at least one fully fluorinated carbon atom.

2. Required coverage. A carrier offering a health plan in this State shall provide coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances that is recommended by a provider as medically necessary health care for an enrollee. For the purposes of this subsection, blood testing for PFAS is presumed to be medically necessary health care for an enrollee if a provider determines that the enrollee meets clinical guidelines for blood testing for PFAS established by the National Academies of Sciences, Engineering, and Medicine, its successor organization or a comparable organization.

Sec. 2. Application. This Act applies to all policies, contracts and certificates executed, delivered, issued for delivery, continued or renewed in this State on or after January 1, 2027. For purposes of this Act, all contracts are deemed to be renewed no later than the next yearly anniversary of the contract date.

Sec. 3. Exemption from mandate review. Notwithstanding the Maine Revised Statutes, Title 24-A, section 2752, this Act is enacted without review and evaluation by the Department of Professional and Financial Regulation, Bureau of Insurance.

Sec. 4. Appropriations and allocations. The following appropriations and allocations are made.

**ADMINISTRATIVE AND FINANCIAL SERVICES, DEPARTMENT OF
State Benefit Mandate Defrayal Z373**

Initiative: Provides ongoing funding for the cost of the benefit mandate providing coverage of blood testing for perfluoroalkyl and polyfluoroalkyl substances, beginning January 1, 2027.

GENERAL FUND	2025-26	2026-27
All Other	\$0	\$90,000
GENERAL FUND TOTAL	<u>\$0</u>	<u>\$90,000</u>